April 8, 2020 -- Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic collaboration partners for therapy development.
Since January, the company has designated over 100 expert research and development scientists to contribute to projects for potential treatment solutions for COVID-19. The company has established additional collaborations with academia, biotech, and other pharmaceutical companies.
Additionally, Boehringer Ingelheim has made available $6.4 million in donations for emergency aid. The company is also offering paid leave to join external organizations to bring COVID-19 relief.
Committed to further contributions as needed, the company is working in broad strokes to tackle the virus, according to Cyrille Kuhn, PhD, executive director of research at Boehringer Ingelheim.